Close Menu

Breaking News

The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.

The sites include Massachusetts General Hospital, Northwestern Medicine, Struthers Parkinson's Center, UC San Diego, and the Perelman School of Medicine.

The UK-based company's revenues are generated exclusively from epigenetic biomarker research and development alliances with commercial and academic partners.

In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.

The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.

The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.

The Genome Program, led by technology firm Group 42 in collaboration with BGI and Oxford Nanopore, plans to sequence 100,000 samples during its first phase.

The firm took down all of its global information technology systems following a ransomware attack last Thursday.

The chip will include coding SNPs identified by Medicinal Genomics using its Kannapedia cannabis genomic database, according to Eurofins.

Verogen will gain access to GEDmatch's database of genetic profiles, although users can choose whether law enforcement can search their data to solve violent crimes.

The company said it will use the funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform.

Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.

The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.

Researchers demonstrated the importance of integrating mutational and transcriptomic profiles to improve understanding of AML and MDS patients' prognosis.

The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.

The partnership is intended to add new assays to the NeuMoDx MDx menu, including tests for post-transplant infections, pharmacogenetics applications, and others.

Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.

A group of researchers devised a DNA-based storage system that uses DNA molecules to record data and produces materials with immutable memory.

They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.

The study, presented at the American Society of Hematology meeting, also suggested that a moleculary guided strategy may lead to better outcomes than standard of care.

Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.

The firm is offering  24.6 million shares of its common stock and warrants to purchase 24.6 million shares of stocks to financially  support and expand its business.

An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.

Last week, GenomeWeb's readers were most interested in Veritas Genetics' decision to halt its US operations.

The new tool can provide a more accurate and unbiased view of the multiple outcomes of CRISPR-based gene editing, according to the developers.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.